drugset / Trial / NCT00835536

Ribavirin 200 mg Tablets Under Non-Fasting Conditions

NCT00835536

Phase 1 Completed 27 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to compare the relative bioavailability of ribavirin 200 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of COPEGUS™ 200 mg tablets (Roche) in healthy, adult, non-smoking, females (who are unable to become pregnant) under non-fasting conditions.

Timeline

Start
2003-09
Primary completion
2003-10
Completion
2003-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule 200 mg

Indications

No indication recorded.